Ocugen Secures Key U.S. Patent for Gene Therapy in Retinal Diseases, Advancing Broad Treatment Potential

Ocugen Secures Key U.S. Patent for Gene Therapy in Retinal Diseases, Advancing Broad Treatment Potential

For individuals and families navigating the challenges of inherited retinal diseases (IRDs), news of advancements in gene therapy offers a beacon of hope. Ocugen, Inc., a clinical-stage biopharmaceutical company, recently announced the issuance of a significant U.S. patent that could pave the way for broader treatment options for various retinal degenerative conditions. This development is particularly relevant to the IRD community, as it underscores ongoing efforts to address the underlying genetic causes of vision loss.

Key Patent Details and What It Means

On June 7, 2022, the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,351,225 to Ocugen, Inc.. This patent specifically covers the use of nuclear hormone receptor genes, such as NR2E3, RORA, NUPR1, and NR2C1, for treating retinal degenerative diseases and reducing the risk of their development. The patent also includes claims related to treating specific conditions like retinitis pigmentosa (RP), age-related macular degeneration (AMD), and other inherited retinal degenerative diseases. This patent, which contains 18 claims, is exclusive to Ocugen through an exclusive license agreement with The Schepens Eye Research Institute, an affiliate of Harvard Medical School, and is set to expire in March 2034.

Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen, stated that this patent